Abstract 90P
Background
Immune surveillance is closely related to MHC and its associated molecules. The MHC class I chain related B molecule (MICB) is one of the ligands of NKG2D receptor. NKG2D receptor exists in NK cells and CD8+ T cells, which mediate anti-tumor response and immune surveillance. MICB is expressed by intestinal epithelium and epithelial tumors as well. Cancer cells express MICB as the consequence of cellular stress. But tumor cells might develop evasive pathways to avoid NK cell attack. Shedding is a way for cancer cells to remove or avoid the surface expression of MICB. Previous studies haven’t clearly figured out the prognostic value of MICB in colorectal cancer (CRC). Here, we figured out the relationship between MICB and prognosis in a CRC cohort of Zhongshan Hospital. The prognostic benefit was also validated in GSE39582 from Gene Expression Omnibus repository.
Methods
863 consecutive CRC patients from 2008 to 2012 without prior treatment were enrolled. 556 CRC patients between 1987 to 2007 were collected from GSE39582. MICB was detected by immunochemistry. MICB score equaled MICB intensity multiplied by the percentage of positive cells among all tumor cells. The cut-off value of MICB score was calculated by X-tile. The association between clinicopathological features and MICB were accessed by chi-square test. Kaplan-Meier analysis and log-rank test were performed to evaluate the relationship between MICB and overall survival. Univariate and multivariate cox regression analyses were performed to identify the independent prognostic factors.
Results
High MICB was significantly associated with non-mucinous histological type (p < 0.001) and ≤4.0cm tumor size (p = 0.001). Kaplan-Meier analyses and log-rank test showed high MICB group had a better overall survival (p = 0.002). In cox regression analyses of Zhongshan cohort, MICB was confirmed as an independent prognostic factor of OS (p = 0.008, HR = 0.741, 95% CI = 0.594-0.924).
Conclusions
MICB was identified as a new independent prognostic factor in stage one to stage four CRC patients. CRC with high MICB expression conferred survival benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract